plekhh1 Antibody

What is PLEKHH1 and what is its significance in research?

PLEKHH1, also known as KIAA1200, is a pleckstrin homology domain-containing protein with a calculated molecular weight of approximately 151 kDa. It belongs to the pleckstrin homology domain-containing family H and contains MyTH4 domains . The protein is encoded by the gene located on chromosome 14q24.1 and is associated with cytoskeletal functions .

PLEKHH1 is significant in research due to its structural domains that suggest roles in cellular signaling and cytoskeletal organization. The pleckstrin homology (PH) domains typically bind phosphoinositides and are involved in membrane targeting. The presence of MyTH4 domains indicates potential involvement in cytoskeletal protein interactions, making PLEKHH1 antibodies valuable tools for investigating cellular architecture and signaling pathways.

What types of PLEKHH1 antibodies are available for researchers?

Researchers have multiple options for PLEKHH1 antibodies, each with distinct characteristics suitable for different experimental approaches:

The monoclonal antibody offers high specificity to a single epitope, while polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals but with increased background potential .

How do I determine which PLEKHH1 antibody is most suitable for my specific research question?

Selecting the appropriate PLEKHH1 antibody depends on several experimental factors:

For detection of specific isoforms, consider antibodies targeting regions unique to your isoform of interest. PLEKHH1 has at least two isoforms produced by alternative splicing . Monoclonal antibodies provide higher specificity for discriminating between similar epitopes, particularly relevant when studying proteins with high homology to PLEKHH1 .

Application requirements should guide selection—for example, if performing immunohistochemistry on paraffin-embedded sections, ensure the antibody has been validated for IHC(p) . Species compatibility is crucial; available PLEKHH1 antibodies show reactivity to human and mouse samples, but experimental validation in your specific model system is recommended .

For studies requiring quantification, consider antibodies validated for quantitative applications like ELISA or flow cytometry .

What are the recommended protocols for using PLEKHH1 antibodies in Western blotting?

For Western blot applications using PLEKHH1 antibodies, follow these methodological considerations:

• Sample preparation: Prepare cell or tissue lysates using standard protocols with protease inhibitors to prevent protein degradation.

• Gel selection: Since PLEKHH1 has a calculated molecular weight of approximately 151 kDa, use low percentage gels (6-8%) for optimal resolution of high molecular weight proteins .

• Antibody dilution: For polyclonal antibodies, a 1:1000 dilution is typically recommended for Western blot applications . Optimize dilutions through titration experiments.

• Detection: Both monoclonal and polyclonal PLEKHH1 antibodies have demonstrated successful detection in cell lines such as HepG2 .

• Expected bands: Be prepared to observe the full-length protein at approximately 151 kDa, but also potential bands at around 30 kDa that may represent proteolytic fragments or isoforms .

• Controls: Include positive controls such as HepG2 cell lysates, which have demonstrated detectable levels of PLEKHH1 protein .

How should I optimize PLEKHH1 antibody use in immunohistochemistry?

For effective immunohistochemical (IHC) detection of PLEKHH1:

• Tissue processing: Both formalin-fixed paraffin-embedded (FFPE) and frozen sections can be used. PLEKHH1 antibodies have been validated in FFPE human kidney and brain tissues .

• Antigen retrieval: This critical step should be optimized based on fixation methods. For FFPE samples, heat-induced epitope retrieval in citrate buffer (pH 6.0) is commonly effective.

• Blocking and antibody incubation: Use appropriate blocking solutions to reduce background. For polyclonal antibodies, longer incubation times (overnight at 4°C) may yield better results.

• Detection systems: Both mouse monoclonal and rabbit polyclonal PLEKHH1 antibodies are compatible with standard secondary detection systems. For enhanced sensitivity, consider peroxidase-based amplification systems as used in published protocols .

• Validation: PLEKHH1 expression has been documented in human kidney and brain tissues, which can serve as positive controls for IHC optimization .

What approaches should I take when using PLEKHH1 antibodies in flow cytometry?

For flow cytometry applications with PLEKHH1 antibodies:

• Cell preparation: Single-cell suspensions must be properly fixed and permeabilized since PLEKHH1 is primarily intracellular due to its cytoskeletal association .

• Antibody selection: Choose antibodies specifically validated for flow cytometry. Rabbit polyclonal antibodies targeting the C-terminal region (AA 1082-1110) have demonstrated successful application in flow cytometry .

• Controls and gating strategy: Use isotype controls appropriate for your primary antibody. K562 cells have been used successfully in flow cytometry applications with PLEKHH1 antibodies and can serve as positive controls .

• Signal detection: For unconjugated antibodies, select appropriate fluorophore-conjugated secondary antibodies. FITC-conjugated donkey-anti-rabbit secondary antibodies have proven effective with PLEKHH1 primary antibodies .

• Data analysis: When interpreting flow cytometry data, compare histogram shifts relative to negative controls to accurately assess PLEKHH1 expression levels.

How can I validate PLEKHH1 antibody specificity for critical experiments?

Antibody specificity validation is essential for reliable research outcomes:

• Knockout/knockdown controls: Generate PLEKHH1 knockdown or knockout samples to confirm antibody specificity. The absence of signal in these samples would verify specificity.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application. Specific binding should be blocked by the peptide, resulting in reduced or absent signal .

• Multiple antibody validation: Compare results using different antibodies targeting distinct epitopes of PLEKHH1. Consistent results across different antibodies increase confidence in specificity .

• Cross-reactivity assessment: Test the antibody against related family members with similar domains to ensure specificity to PLEKHH1 rather than related proteins.

• Multi-application validation: Confirm consistent results across different applications (WB, IHC, FACS) to strengthen confidence in antibody specificity .

What strategies can resolve contradictory results between different PLEKHH1 antibodies?

When faced with contradictory results:

• Epitope mapping: Different antibodies target different regions of PLEKHH1. The monoclonal antibody recognizes recombinant protein epitopes, while available polyclonal antibodies target C-terminal regions (AA 1082-1118). These differences may explain varying results if post-translational modifications or protein interactions obscure specific epitopes .

• Isoform specificity: PLEKHH1 has at least two isoforms. Determine if contradictory results stem from isoform-specific detection by examining the antibodies' target regions relative to known isoform structures .

• Methodological optimization: Different antibodies may require distinct optimization protocols. Adjust parameters including antibody concentration, incubation time, and detection methods .

• Systematic bias analysis: Examine potential biases in different experimental approaches. For example, recent research has highlighted how selection experiments can introduce artifacts that may influence antibody binding profiles .

• Biophysics-informed modeling: Advanced computational approaches can help disentangle multiple binding modes associated with specific antibodies, potentially explaining contradictory results between different antibodies .

How can I utilize PLEKHH1 antibodies for studying protein-protein interactions?

For protein interaction studies:

• Co-immunoprecipitation (Co-IP): Use PLEKHH1 antibodies for pull-down experiments to identify interacting partners. Both monoclonal and polyclonal antibodies can be used, though monoclonal antibodies may provide cleaner results with less background .

• Proximity ligation assays (PLA): Combine PLEKHH1 antibodies with antibodies against suspected interaction partners to visualize protein proximity in situ.

• Optimization considerations: Given PLEKHH1's cytoskeletal association, interaction studies may require specialized lysis conditions to maintain protein complexes while effectively solubilizing membrane and cytoskeletal components .

• Controls: Include antibody-only controls and non-specific antibody controls of the same isotype to distinguish specific from non-specific interactions.

• Validation approaches: Confirm identified interactions through reciprocal Co-IP and orthogonal methods such as yeast two-hybrid or bimolecular fluorescence complementation.

Why might I observe multiple bands in Western blot with PLEKHH1 antibodies?

Multiple bands in Western blots can result from several factors:

• Isoforms: PLEKHH1 is known to have at least two isoforms produced by alternative splicing . The calculated molecular weight of PLEKHH1 is reported as "151/30 kDa," suggesting potential detection of both full-length protein and smaller variants .

• Proteolytic degradation: Inadequate sample preparation or storage can lead to protein degradation, resulting in multiple bands. Ensure samples are prepared with appropriate protease inhibitors and avoid repeated freeze-thaw cycles.

• Post-translational modifications: Modifications like phosphorylation, glycosylation, or ubiquitination can alter protein mobility on gels, resulting in additional bands or mobility shifts.

• Cross-reactivity: Although antibodies are designed to be specific, some degree of cross-reactivity with structurally similar proteins may occur, particularly with polyclonal antibodies. Perform additional specificity controls if this is suspected .

• Non-specific binding: High antibody concentrations can increase non-specific binding. Optimize antibody dilutions and blocking conditions to minimize this issue.

How can I address inconsistent staining patterns in IHC with PLEKHH1 antibodies?

To address inconsistent immunohistochemical staining:

• Fixation optimization: Different fixation methods can affect epitope availability. Compare results between different fixation protocols, particularly if targeting the C-terminal region (AA 1082-1118) .

• Antigen retrieval customization: Test multiple antigen retrieval methods (heat-induced vs. enzymatic, different pH buffers) to optimize epitope exposure.

• Tissue-specific considerations: PLEKHH1 antibodies have shown successful staining in human kidney and brain tissues . Staining patterns may naturally vary between different tissues based on protein expression levels and cellular localization.

• Detection system sensitivity: For weakly expressed targets, consider amplification systems like tyramide signal amplification to enhance detection sensitivity.

• Batch-to-batch variability: Document lot numbers and prepare large batches of working dilutions to minimize variability between experiments.

What emerging techniques might enhance PLEKHH1 antibody application in research?

Several emerging approaches show promise:

• Computational antibody design: Recent advances in biophysics-informed modeling allow for the design of antibodies with customized specificity profiles. This approach could be applied to develop PLEKHH1 antibodies with enhanced specificity for particular epitopes or applications .

• High-throughput sequencing integration: Combining antibody selection with high-throughput sequencing and computational analysis offers additional control over specificity profiles, enabling the design of antibodies that can discriminate between very similar epitopes .

• Multiplexed detection systems: New multiplexed imaging technologies allow simultaneous detection of multiple proteins, enabling studies of PLEKHH1 in the context of its interaction partners and cellular environment.

• Single-cell applications: Adapting PLEKHH1 antibodies for single-cell proteomics would allow assessment of protein expression heterogeneity across cell populations.

• Nanobody development: Smaller antibody fragments derived from conventional antibodies may provide enhanced tissue penetration and reduced background in certain applications.

What controls are essential when designing critical experiments with PLEKHH1 antibodies?

For robust experimental design:

• Positive controls: Include samples known to express PLEKHH1, such as human kidney tissue for IHC or HepG2/K562 cell lysates for Western blot and flow cytometry .

• Negative controls: Samples with PLEKHH1 knockdown/knockout provide ideal negative controls. Alternatively, samples from tissues known not to express PLEKHH1 can be used.

• Isotype controls: Include matching isotype controls (mouse IgG for monoclonal or rabbit IgG for polyclonal antibodies) to assess non-specific binding .

• Peptide competition: Pre-absorption of the antibody with immunizing peptide provides a specificity control, particularly valuable for polyclonal antibodies .

• Technical replicates: Include technical replicates to ensure reproducibility and allow statistical analysis of results.

• Cross-antibody validation: When possible, confirm key findings using multiple PLEKHH1 antibodies targeting different epitopes .